SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 5,000 Shares of Stock

Key Points

• Insider selling: SOPHiA GENETICS insider Philippe Menu sold 5,000 shares on June 25 at an average price of $5.50, worth $27,500, reducing his ownership by 2.03%. The trade was made under a pre-arranged Rule 10b5-1 plan.
• Stock performance: SOPH shares rose 1.1% to $5.75 on Friday, trading above both its 50-day and 200-day moving averages. The stock has ranged from a 52-week low of $2.81 to a high of $5.94.
• Recent results and outlook: The company reported a quarterly loss of $0.27 per share, missing estimates, though revenue of $21.69 million came in above expectations. Analysts currently rate the stock a Hold with a consensus price target of $7.50.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $5.50, for a total transaction of $27,500.00. Following the completion of the sale, the insider owned 240,780 shares of the company's stock, valued at $1,324,290. This trade represents a 2.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.95, for a total transaction of $24,750.00.
• On Monday, April 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.82, for a total transaction of $24,100.00.
• On Monday, April 20th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.20, for a total transaction of $3,161.60.
• On Tuesday, April 14th, Philippe Menu sold 1,600 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.96, for a total transaction of $7,936.00.
• On Monday, April 13th, Philippe Menu sold 4,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total transaction of $20,944.00.
• On Friday, April 10th, Philippe Menu sold 3,725 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.68, for a total transaction of $17,433.00.
• On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,152.94.
• On Wednesday, April 8th, Philippe Menu sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total value of $11,688.00.
• On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total value of $13,095.00.

SOPHiA GENETICS Stock Up 1.1%

Shares of NASDAQ:SOPH traded up $0.06 on Friday, reaching $5.75. The company had a trading volume of 423,880 shares, compared to its average volume of 174,550. The stock has a market capitalization of $482.37 million, a P/E ratio of -11.06 and a beta of 0.98. The stock has a 50-day moving average price of $5.06 and a 200 day moving average price of $4.92. SOPHiA GENETICS SA has a twelve month low of $2.81 and a twelve month high of $5.94. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The company had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million.

Institutional Trading of SOPHiA GENETICS

Hedge funds have recently bought and sold shares of the stock. Perkins Capital Management Inc. acquired a new stake in SOPHiA GENETICS in the 4th quarter worth $49,000. Squarepoint Ops LLC acquired a new position in shares of SOPHiA GENETICS during the third quarter valued at about $49,000. First Dallas Securities Inc. acquired a new position in shares of SOPHiA GENETICS during the first quarter valued at about $50,000. Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $54,000. Finally, XTX Topco Ltd bought a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $55,000. 31.59% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

SOPH has been the topic of a number of recent analyst reports. BTIG Research reissued a "buy" rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, SOPHiA GENETICS currently has a consensus rating of "Hold" and a consensus price target of $7.50.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.